Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response observed in adenocarcinoma.

被引：0
|
作者：
Ilson, D. [1 ]
Shah, M. A. [1 ]
Kelsen, D. P. [1 ]
Janjigian, Y. Y. [1 ]
Tang, L. H. [1 ]
Campbell, J. [1 ]
Fuqua, L. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e14668
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14668
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response observed in adenocarcinoma
    Ilson, D.
    Janjigian, Y. Y.
    Shah, M. A.
    Tang, L. H.
    Kelsen, D. P.
    Campbell, J.
    Fuqua, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [2] Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response and protracted stable disease observed in adenocarcinoma.
    Ilson, D.
    Janjigian, Y. Y.
    Shah, M. A.
    Kelsen, D. P.
    Tang, L. H.
    Campbell, J.
    Fuqua, L.
    Capanu, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response and prolonged stable disease observed in adenocarcinoma
    Ku, Geoffrey Y.
    Janjigian, Yelena Yuriy
    Shah, Manish A.
    Herrera, Jessica
    Tang, Laura H.
    Fuqua, Louis
    Capanu, Marinela
    Ilson, David
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [4] Phase Ib/II trial of durvalumab and chemoradiation (CRT) with carboplatin/paclitaxel for esophageal and gastroesophageal junction (GEJ) adenocarcinoma.
    Greally, Megan
    Molena, Daniela
    Sihag, Smita
    Wu, Abraham Jing-Ching
    Shah, Pari M.
    Fein, Carly
    Capanu, Marinela
    Kelsen, David Paul
    Janjigian, Yelena Yuriy
    Ilson, David H.
    Ku, Geoffrey Yuyat
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [5] Phase II trial of gefitinib for recurrent or metastatic esophageal or gastroesophageal junction (GEJ) cancer.
    Adelstein, DJ
    Rybicki, LA
    Carroll, MA
    Rice, TW
    Mekhail, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 321S - 321S
  • [6] Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer
    Janjigian, Yelena Y.
    Vakiani, Efsevia
    Ku, Geoffrey Y.
    Herrera, Jessica M.
    Tang, Laura H.
    Bouvier, Nancy
    Viale, Agnes
    Socci, Nicholas D.
    Capanu, Marinela
    Berger, Michael
    Ilson, David H.
    PLOS ONE, 2015, 10 (08):
  • [7] A phase II study of TAS-102 in combination with ramucirumab in advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma.
    Mehta, Rutika
    Kim, Richard D.
    Shah, Neal
    Carballido, Estrella M.
    Kim, Youngchul
    Imanirad, Iman
    Kim, Dae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma.
    Li, Hongli
    Deng, Jingyu
    Ge, Shaohua
    Zang, Fenglin
    Zhang, Le
    Ren, Peng
    Wang, Baogui
    Cao, Fuliang
    Deng, Ting
    Liu, Rui
    Ning, Tao
    Yang, Yuchong
    Bai, Ming
    Wang, Xia
    Ji, Zhi
    Duan, Jingjing
    Liu, Yong
    Zhou, Dejun
    Liang, Han
    Ba, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Phase II study of neoadjuvant FLOT and chemoradiation for trimodality therapy of esophageal/GEJ adenocarcinoma.
    Olsen, Jeffrey R.
    Leal, Alexis Diane
    Kim, Sunnie S.
    Goodman, Karyn A.
    Binder, David
    Blum, Matthew
    Erickson, Crystal
    Hoyer, Robert John
    Kemme, Douglas Jerome
    Lieu, Christopher Hanyoung
    Liu, Arthur
    Marsh, Megan
    Mathew, Lynn
    McCarter, Martin
    Messersmith, Wells A.
    Petit, Joshua H.
    Shonebarger, Daniel
    Waxweiler, Timothy, V
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 466 - 466
  • [10] Phase I/II trial of perioperative avelumab in combination with chemoradiation (CRT) in the treatment of stage II/III resectable esophageal and gastroesophageal junction (E/GEJ) cancer.
    Uboha, Nataliya Volodymyrivna
    Eickhoff, Jens C.
    Maloney, James D.
    McCarthy, Daniel
    DeCamp, Malcolm
    Deming, Dustin A.
    LoConte, Noelle K.
    Matkowskyj, Kristina A.
    Patel, Monica Arun
    Hurst, Newton
    Kratz, Jeremy D.
    Lubner, Sam Joseph
    Bassetti, Michael Frederick
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345